Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Methylselenocysteine treatment leads to diselenide formation in human cancer cells: evidence from X-ray absorption spectroscopy studies|
|Citation:||Biochemistry, 2012; 51(3):736-738|
|Publisher:||American Chemical Society|
|Claire M. Weekley, Jade B. Aitken, Ian F. Musgrave, and Hugh H. Harris|
|Abstract:||The selenoamino acids methylselenocysteine (MeSeCys) and selenomethionine (SeMet) have disparate efficacies as anticancer agents. Herein, we use X-ray absorption spectroscopy to determine the chemical form of selenium in human neuroblastoma cells. Cells treated with MeSeCys contain a significant diselenide component, which is absent from SeMet-treated cells and suggests that metabolites of MeSeCys are capable of altering the redox status of the cells. The differences in the speciation of Se in the selenoamino acid-treated cells may provide insight into the differing anticancer activities of MeSeCys and SeMet.|
|Keywords:||Cell Line, Tumor; Humans; Selenium Compounds; Benzene Derivatives; Organoselenium Compounds; Selenocysteine; Cysteine; Antineoplastic Agents; X-Ray Absorption Spectroscopy|
|Rights:||Copyright © 2012 American Chemical Society|
|Appears in Collections:||IPAS publications|
Environment Institute publications
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.